India, the largest democracy and the tenth largest economy in the world, has seen growth rates over the last decade that many of its Western counterparts would envy. In no other industry is India’s recent growth more apparent than in pharmaceuticals. With the market estimated to have been at $6 billion in 2005, a threefold increase was seen in just seven years, as it expanded to $18 billion in 2012. India now accounts for approximately 1.4% of the global pharmaceutical industry in value and 10% in volume. McKinsey & Company projects that it will reach $45 billion by 2020.

This growth has been driven largely by the manufacture of active pharmaceutical ingredients (APIs), but the industry will need to evolve to maintain its growth. With a large number of drugs coming off patent in the coming years, including $90 billion in 2015, and becoming available to international players, it is expected that more Indian companies will have income to start increasing their investment in research and development (R&D). Though the recent wave of sanctions filed by the U.S. FDA against major Indian companies for inadequacies in their quality control has raised concerns, the past record of the Indian pharmaceuticals industry indicates that it will likely evolve and flourish in the coming years.

Featuring exclusive interviews with:

Aurobindo – N. Govindarajan, Managing Director
Biocon – Kiran Mazumdar-Shaw, Chairperson and Managing Director
Cipla Ltd. – Subhanu Saxena, Managing Director & Global CEO
Glenmark – Glenn Saldanha, Chairman and Managing Director
GSK – Hasit. B. Joshipura, Managing Director
IBEF – Aparna Dutt Sharma, CEO
Lupin – Ramesh Swaminathan, CEO
Ministry of Commerce & Industry, Government of India – Shri Sudhanshu Pandey, Joint Secretary
Pharmexcil – Dr. P V Appaji, Director General
Piramal Enterprises Ltd. – Vivek Sharma, CEO Pharma Solutions & Critical Care
Sun Pharma – Abhay Gandhi, CEO India
Supriya Lifescience – Satish W. Wagh, Chairman and Managing Director